Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy

Clinical Breast Cancer

Volumn 6, Issue 4, 2005, Pages 354-356

  Fanale, Michelle A ^a   Uyei, Anne R ^a   Theriault, Richard L ^a   Adam, Karolina ^b   Thompson, Rachel A ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c Houston Women's Care Associates   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Cyclophosphamide; Magnetic resonance imaging; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; INFUSION FLUID; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETOTOXICITY; FETUS MONITORING; GENE OVEREXPRESSION; GESTATION PERIOD; HIGH RISK PREGNANCY; HUMAN; LABOR INDUCTION; LIVER METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MASTECTOMY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; PAGET NIPPLE DISEASE; PREGNANCY COMPLICATION; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 28344451882     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.040     Document Type: Article

References (18)

1. Wallack MK, Wolf JA Jr, Bedwinek J, et al. Gestational carcinoma of the female breast. Curr Probl Cancer 1983; 7:1-58.
2. Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001; 184:1504-1512.
3. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997; 74:207-220.
4. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989; 16:337-346.
5. Berry DL, Theriault RL, Holmes FA, et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999; 17:855-861.
6. Gwyn K, Theriault R, Sahin A., et al. Treatment of breast cancer during pregnancy ssing a standard protocol: update of the M.D. Anderson experience. Proc Am Soc Clin Oncol 2001; 18b (Abstract #1821).
7. De Santis M, Lucchese A, De Carolis S, et al. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 2000; 9:235-237.
8. Cuvier C, Espie M, Extra JM, et al. Vinorelbine in pregnancy. Eur J Cancer 1997; 33:168-169.
9. Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 1999; 86:2266-2272.
10. Janne PA, Rodriguez-Thompson D, Metcalf DR, et al. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy. Oncology 2001; 61:175-183.
11. Rodriguez JM, Haggag M. VACOP-B chemotherapy for high grade non-Hodgkin's lymphoma in pregnancy. Clin Oncol (R Coll Radiol) 1995; 7:319-320.
12. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in the first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safey of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
14. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
15. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial for weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7:410-417.
16. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-2895.
17. Genetech Pharmaceuticals Website. Full Prescribing Information of Herceptin (Trastuzumab)--Precautions. 2003. Available at: http://www.gene.com/gene/products/information/oncology/herceptin/ insert.jsp. Accessed October 22, 2004.
18. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394-398.